I.TO News 3.89 Intellipharmaceutics International Inc. (I.TO

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Intellipharmaceutics International Inc. (I.TO) 3.89 $I.TO

Intellipharmaceutics achieves net income of USD2.2m in Q1 2014
M2 - Tue Apr 15, 4:23AM CDT
Pharmaceutical company Intellipharmaceutics International (NasdaqCM:IPCI) (TSX:I) on Monday disclosed its net income of USD2.2m (USD0.09 per diluted common share) for the three months ended 28 February 2014.

Intellipharmaceutics Announces First Quarter 2014 Results
GlobeNewswire - Mon Apr 14, 6:01AM CDT
Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today reported the results of operations for the three months ended February 28, 2014. All dollar amounts referenced herein are in United States dollars unless otherwise noted.

Intellipharmaceutics -- Amended Form of Proxy for Shareholders Meeting to be Held on March 27, 2014
GlobeNewswire - Wed Mar 19, 4:00PM CDT
Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced that it has sent to registered shareholders an amended form of proxy for voting at its annual and special shareholders meeting to be held on March 27, 2014 (the "Meeting".

Correction - Mackie Research Capital Initiates Coverage on Intellipharmaceutics Intl (NASDAQ:IPCI) (TSX:I) with a Speculative Buy Recommendation - Video Research Alert on InvestmentPitch.com
Thomson Reuters ONE - Mon Mar 17, 9:59AM CDT
Vancouver, BC, March 17, 2014 - Investment firm Mackie Research has initiated coverage on Intellipharmaceutics International, (NASDAQ:IPCI) (TSX:I). Analyst Andre Uddin gives the company a speculative buy recommendation and 12-month target of US$11.00, a premium of 140% to the $4.58 price on March 12th, the day the report was issued.

Jennings Capital Initiates Coverage on Intellipharmaceutics Intl (NASDAQ:IPCI) (TSX:I) with a Speculative Buy Recommendation - Video Research Alert on InvestmentPitch.com
Thomson Reuters ONE - Fri Mar 14, 5:22PM CDT
Vancouver, BC, March 14, 2014 - Investment firm Mackie Research has initiated coverage on Intellipharmaceutics International, (NASDAQ:IPCI) (TSX:I). Analyst Andre Uddin gives the company a speculative buy recommendation and 12-month target of US$11.00, a premium of 140% to the $4.58 price on March 12th, the day the report was issued.

Intellipharmaceutics to Present at Two Upcoming Investor Conferences
GlobeNewswire - Tue Mar 04, 4:00PM CST
Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, announced today that the Company is scheduled to present at the following two upcoming conferences.

Intellipharmaceutics posts higher net loss in 2013
M2 - Wed Feb 19, 6:11AM CST
Canadian pharmaceutical company Intellipharmaceutics International Inc (NasdaqCM:IPCI) (TSX:I) stated on Tuesday a net loss of USD11.5m (USD0.58 per common share) for the year ended 30 November 2013.

Intellipharmaceutics Announces 2013 Year End Results
GlobeNewswire - Tue Feb 18, 6:05AM CST
Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today reported the results of operations for the year ended November 30, 2013. All dollar amounts referenced herein are in United States dollars unless otherwise noted.

Intellipharmaceutics International Inc awarded first profit-share of USD3.1m from Par Pharmaceuticals Inc for sales of 15 and 30 mg generic Focalin XR
M2 - Tue Feb 04, 4:33AM CST
Pharmaceutical company Intellipharmaceutics International Inc (TSX:I) said on Monday that it has received the first payment of USD3.1m relating to commercial sales of dexmethylphenidate hydrochloride extended-release capsules by its licensee Par Pharmaceutical Inc.

Intellipharmaceutics Receives $3.1 Million From Par Pharmaceuticals, Inc.
GlobeNewswire - Mon Feb 03, 6:00AM CST
- First Profit-Share Payment on 15 and 30 mg Generic Focalin XR(R) Sales

Intellipharmaceutics to Present at the 25th Annual Piper Jaffray Healthcare Conference
GlobeNewswire - Mon Dec 02, 6:00AM CST
Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced that Shameze Rampertab, Vice President Finance and Chief Financial Officer, will present a Company overview at the 25th Annual Piper Jaffray Healthcare Conference at the New York Palace Hotel in New York at 1:00pm EST on Wednesday, December 4, 2013.

Intellipharmaceutics International Inc reports 'at-the-market offering' of 5.31m common shares
M2 - Thu Nov 28, 4:54AM CST
Pharmaceutical company Intellipharmaceutics International Inc (NasdaqCM:IPCI) (TSX:I) stated on Wednesday that it plans to sell up to 5,305,484 of its common shares through an 'at-the-market' offering programme.

Intellipharmaceutics Announces At-The-Market Offering of Common Shares
GlobeNewswire - Wed Nov 27, 3:30PM CST
Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced an "at-the-market" offering program under which it may from time to time sell up to 5,305,484 of its common shares for up to an aggregate of US$16.8 million through at-the-market issuances on the NASDAQ Capital Market.

J.C. Penney, Lowe's, Tesla are big market movers
AP - Wed Nov 20, 3:55PM CST
NEW YORK (AP) — Stocks that moved substantially or traded heavily Wednesday on the New York Stock Exchange and the Nasdaq Stock Market:

Ahead of the Bell: IntelliPharmaCeutics climbs
By The Associated Press - AP - Wed Nov 20, 7:38AM CST
Shares of IntelliPharmaCeutics International Inc. jumped again Wednesday before markets opened, as the generic drug developer continued a strong week that started with a key product approval.

IIROC Trade Resumption - I
CNW Group - Tue Nov 19, 7:32AM CST
Trading resumes in:

Intellipharmaceutics International Inc introduces 15 and 30 mg generic Focalin XR for attention deficit hyperactivity disorder in the market
M2 - Tue Nov 19, 5:34AM CST
Pharmaceutical company Intellipharmaceutics International Inc (TSX:I) revealed on Monday the receipt of final approval from the US Food and Drug Administration (FDA) for its dexmethylphenidate hydrochloride extended-release capsules for the 15 and 30 mg strengths for the treatment of attention deficit hyperactivity disorder.

Intellipharmaceutics / Par to Make Immediate Commercial Launch of 15 and 30 mg Generic Focalin XR(R)
GlobeNewswire - Mon Nov 18, 3:34PM CST
- FDA Issues Final Approval of 15 mg, With 180 Days of Exclusivity, and 30 mg; and

IIROC Trading Halt - I
CNW Group - Mon Nov 18, 3:01PM CST
The following issues have been halted by IIROC:

Intellipharmaceutics International Inc completes USD3.1m in public offering
M2 - Thu Aug 01, 6:19AM CDT
Pharmaceutical company Intellipharmaceutics International Inc (NasdaqCM:IPCI) (TSX:I) announced on Wednesday the completion of its USD3.1m underwritten public offering.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Lecanemab's Alpha-Syn Signal Deserves a Cooler Head

Updated Category News Views 108

Mixed pathology is where Alzheimer's investing gets uncomfortably real, and this new lecanemab readout is a decent reminder that a drug can show promise without settling the argument. Eisai and Biogen presented a Clarity AD cerebrospinal-fluid substudy at CTAD 2026 examining people with early Alzheimer's disease who also tested positive for alpha-synuclein pathology. The...

Continue Reading
AIC Hotel Group's 11 Awards Test Resort Market Reach

Updated Category News Views 89

Eleven Trophies, Four Properties, One Useful Signal Hospitality awards can be a lot of polished brass and very little cash flow, but this batch is substantial enough to deserve a hard look. AIC Hotel Group collected 11 honors spanning Condé Nast Traveler's 2026 Readers' Choice Awards, Travel Weekly's 2026 Magellan Awards, and Good Housekeeping's 2027 Travel Awards. The...

Continue Reading
Nike Locks In Chicago Marathon Partnership Through 2036 Deal

Updated Category News Views 104

Twenty-eight miles of pavement, training plans, and branded shoes are not a quarterly earnings release, but Nike just made a very long-term statement in Chicago. The company and the Bank of America Chicago Marathon have extended their partnership through 2036, preserving a relationship that began in 2008. For a brand rebuilding credibility with runners, that kind of...

Continue Reading
COP31 Puts China’s Weather-to-Energy Model on View

Updated Category News Views 25

Storm maps are becoming operating manuals, and that is the hard reality behind a November 13 COP31 event in Antalya, Türkiye. The session, “From Early Warning to Energy Action: Pathways for Global Climate Diplomacy and Cooperation,” put China’s effort to tie meteorological intelligence to energy-system decisions under an international spotlight. This is not...

Continue Reading
Retainers Are the Unflashy Finish to Orthodontic Care

Updated Category News Views 103

A straight smile has an inconvenient habit of remembering where it came from. That is the plainspoken point in Dr. Michael McClain’s discussion of retainers after braces or Invisalign: the dramatic part of orthodontic treatment may be over when appliances come off, but the maintenance phase has barely started. It is not glamorous, and plenty of people probably wish it...

Continue Reading
Cedars-Sinai and nference Build a Living Data Engine

Updated Category News Views 57

Five million patient histories are not a flashy product demo. They are a serious raw-material advantage, provided the data can be protected, organized, and made useful without turning clinical research into a carnival of loose claims. That is the real weight behind nference's long-term collaboration with Cedars-Sinai, announced November 20, 2026. The pair plan to build a...

Continue Reading
Nvidia Lawsuit Allegations Put Disclosure Risk in Focus

Updated Category News Views 83

A lawsuit notice can turn a roaring chip story sour in a hurry, and this one deserves a cold, careful read rather than the usual internet stampede. DJS Law Group says it has filed a securities class action against NVIDIA, alleging that the company made materially false and misleading statements during a stated class period running from October 9, 2025 through November 8,...

Continue Reading
Point72 Breach Puts Cyber Controls Under the Microscope

Updated Category News Views 116

Two compromised user accounts can turn a supposedly contained cyber problem into a boardroom headache in a hurry. Point72 Asset Management, the global alternative-investment firm founded by Steven A. Cohen in 2014, has reported a social-engineering incident involving accounts that were used to copy files from limited portions of its IT systems. This is not a trading-loss...

Continue Reading
Foresight Solar Insurance Trial Beats Fixed PPA Route

Updated Category News Views 33

Six solar sites and one settled insurance contract have produced a result worth studying, not celebrating with confetti. Foresight and Paratus say their completed renewable-price insurance policy generated a £14.49/MWh net uplift, after premium, against the revenue those assets would have earned under a fixed-price power purchase agreement. In a UK renewables market...

Continue Reading
Winter Leaks Can Lock In Tarrant Sewer Costs for 2027

Updated Category News Views 133

Silent toilet seepage has a nasty habit of turning winter into a twelve-month utility hangover. Tarrant County homeowners are heading into the period when some local cities use household water consumption to calculate residential sewer charges for the following year. That is not the sort of detail anybody enjoys thinking about during the holidays, but ignoring it can be...

Continue Reading

Top 5 Most Recently Viewed Articles

Datamars Innovates Textile Sorting with New RFID Sorti-Cart

Updated Category News Views 169

Revolutionizing Textile Management in Retirement Homes Datamars has recently made a significant impact on the textile management industry with the introduction of their innovative UHF Sorti-Cart. This cutting-edge RFID trolley is specially crafted for collecting and sorting soiled textiles in retirement homes, addressing a common issue: the loss of personal garments...

Continue Reading
Investigating Potential Securities Claims for WAL Investors

Updated Category News Views 216

Rosen Law Firm Investigates Securities Claims for WAL Investors The Rosen Law Firm, renowned for protecting investor rights, is currently investigating securities claims concerning Western Alliance Bancorporation (NYSE: WAL). The inquiry roots from reports that the company might have disseminated materially misleading business information to its shareholders. Your Rights...

Continue Reading
Leadership Changes at Marten Transport: A New Chapter Ahead

Updated Category News Views 196

Significant Leadership Transition at Marten Transport Marten Transport, Ltd. (Nasdaq: MRTN) has announced a pivotal leadership change as Timothy Kohl, their esteemed Chief Executive Officer, prepares to retire on September 30, 2025. This transition signifies a new chapter for the company, with Randolph Marten stepping into the roles of Chairman of the Board and Chief...

Continue Reading
Enhancing Global Trade: Made-in-China.com's Sourcing Season

Updated Category News Views 175

Made-in-China.com Launches Golden Sourcing Season Made-in-China.com has unveiled its annual Golden Sourcing Season, an initiative designed to energize global procurement. This exciting event provides international buyers the chance to interact with trusted Chinese suppliers, negotiate competitive deals, and efficiently source a wide array of products. Although this annual...

Continue Reading
Meridian Health Plan Invests $15 Million to Enhance Care Quality

Updated Category News Views 301

Meridian Health Plan Enhances Care Quality with Major Investment Meridian Health Plan of Illinois (NYSE: CNC) is making significant strides in the healthcare industry by investing $15 million into initiatives focused on improving health outcomes. This substantial financial commitment is aimed at enhancing the quality of care provided to over 340,000 Medicaid members...

Continue Reading